Sourcebio International (LON:SBI) Trading Down 2.6%

Shares of Sourcebio International Plc (LON:SBIGet Rating) were down 2.6% on Thursday . The company traded as low as GBX 121.62 ($1.48) and last traded at GBX 121.75 ($1.48). Approximately 8,894 shares were traded during trading, a decline of 85% from the average daily volume of 59,894 shares. The stock had previously closed at GBX 125 ($1.52).

Separately, Liberum Capital boosted their target price on Sourcebio International from GBX 210 ($2.55) to GBX 220 ($2.67) and gave the stock a “buy” rating in a report on Tuesday, April 5th.

The company has a market capitalization of £92.73 million and a price-to-earnings ratio of 5.33. The company has a debt-to-equity ratio of 26.90, a quick ratio of 2.81 and a current ratio of 3.21. The firm has a fifty day moving average price of GBX 124.18 and a 200-day moving average price of GBX 131.99.

In related news, insider Jay LeCoque bought 100,000 shares of Sourcebio International stock in a transaction dated Wednesday, April 6th. The shares were bought at an average cost of GBX 129 ($1.57) per share, with a total value of £129,000 ($156,572.40).

About Sourcebio International (LON:SBI)

Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, and the United States. The company's services cover histopathology reporting and human tissue testing services; genomics services to pharmaceuticals, biotechnology, life science, and academic markets; stability storage solutions; and COVID-19 antigen PCR testing services.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Sourcebio International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sourcebio International and related companies with's FREE daily email newsletter.